Season 2: IMPACT II: Impacting Multiple Myeloma in All CommuniTiesUnlock insights into the treatment of multiple myeloma within underrepresented racial and ethnic populations with this series of three enlightening podcast episodes. Join experts from both academic and community oncology settings as they dive into critical aspects of clinical risk, survival outcomes, and treatment considerations.Episode 1: Uncover the factors influencing outcomes for multiple myeloma patients from underrepresented racial and ethnic groups with Dr. Shah.Episode 2: Join Dr. Ailawadhi in exploring a hypothetical scenario of equal conditions and envision how mortality and survival outcomes may differ for multiple myeloma patients from underrepresented groups. Episode 3: Gain valuable insights from Dr. Hartley-Brown as she discusses therapeutic considerations for both current and emerging agents tailored to multiple myeloma patients from underrepresented racial and ethnic backgrounds.Are you ready to expand your understanding of multiple myeloma treatment disparities? Listen to Season 2 of HemeTalks on Apple Podcasts, Spotify, Google Podcasts, or your preferred podcast platform! Don't forget to bookmark the ASH Podcast webpage for easy access.Coming Soon ASH Academy On Demand!Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.Music: "PeriTune - Investigation2(Suspense-Royalty Free Music)" by PeriTune is licensed under CC BY 3.0.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related